Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Materialtyp: Artigo
Språk:Russo
Publicerad: ABV-press 2014-11-01
Serie:Onkourologiâ
Ämnen:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Länkar:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk